Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Anakinra for Preterm Infants Pilot

Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.

anakinra
  • 0 views
  • 13 Jun, 2022
  • 1 location
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities

ejection fraction
ipilimumab
pembrolizumab
nervous system disorder
follicular lymphoma
  • 0 views
  • 10 Nov, 2021
Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients

The ACO/ARO/AIO-21 investigator-driven, open-labeled, phase I drug re-purposing trial will assess whether the IL-1 receptor antagonist Anakinra can be safely combined with fluoropyrimidine-based

chemoradiotherapy
total mesorectal excision
abdominoperineal resection
adenocarcinoma
permanent colostomy
  • 0 views
  • 02 Sep, 2021
  • 1 location
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (Hypo-PrEA)

This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.

  • 0 views
  • 01 May, 2022
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

. Objective To see if a drug called anakinra can help clear inflammation in MS brain lesions. Eligibility People 18 and older

MRI
nervous
disease or disorder
  • 3 views
  • 17 Jun, 2022
  • 1 location
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene

absolute neutrophil count
ejection fraction
ipilimumab
pembrolizumab
follicular lymphoma
  • 0 views
  • 29 Jan, 2021
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial (AFFECT-2)

anakinra, a recombinant human IL-1 receptor antagonist in adult patients with multiple myeloma receiving high-dose melphalan (HDM) in the preparation for an autologous hematopoietic stem cell

cell transplantation
melphalan
fever
chemotherapy regimen
  • 7 views
  • 16 May, 2022
  • 2 locations
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.

experimental drug
hematologic malignancy
cell therapy
cancer
oxygen saturation
  • 1 views
  • 08 Jun, 2022
  • 1 location
Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation (Ana4CKD)

comorbidities including mellitus diabetes type 2, hypertension, obesity and dyslipidemia. Anakinra, an IL-1b receptor antagonist, is efficient in gout flare in patients without CKD stage 4/5. The aim of

  • 0 views
  • 20 Jun, 2022
Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2 (REDHART2)

REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in

edema
hscrp
ejection fraction
anakinra
  • 0 views
  • 01 Mar, 2022
  • 1 location